G1 Therapeutics Inc 's ROA from the second quarter of 2024 to the second quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is G1 Therapeutics Inc 's ROA in the second quarter of 2024?
G1 Therapeutics Inc recorded a cumulative net loss of $-45 million during 12 months ending in the second quarter of 2024, resulting in a negative return on assets (ROA) of -40.56%.

However, within the Healthcare sector 554 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2024 from 3861 to 4119.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter	(Dec 31 2023) IV. Quarter	(Sep 30 2023) III. Quarter	(Jun 30 2023) II. Quarter
Y / Y Total Assets Change	-33.53 %	-37.15 %	-35.46 %	-19.86 %	-20.63 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-45	-31	-48	-71	-78
Return On Assets (TTM)	-40.56 %	-25 %	-35.01 %	-46.15 %	-48.25 %
GTHX's Total Ranking	# 4119	# 3861	# 4692	# 4396	# 4536
Total Assets (TTM) in million	95	99	118	129	143
Seq. Total Assets Change	-4.07 %	-16.24 %	-7.99 %	-10.1 %	-9.29 %
Seq. Net Income Change	-	-	-	-	-

GTHX's 5 Years Annual ROA >> Back to GTHX Management Effectiveness >> Compare GTHX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 224
Sector	# 555
Overall	# 4047

Return On Assets Statistics
High	Average	Low
-24.25 %	-46.52 %	-77.7 %
(Mar 31 2024)		(Dec 31 2022)

Financial Statements
G1 Therapeutics Inc 's Assets	$ 95 million	GTHX's Balance sheet
G1 Therapeutics Inc 's Income	$ -5 million	Quarterly GTHX's Income Statement
GTHX's Income by Division		See GTHX's Income by Division

Annual Return On Assets	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020	(Dec 31 2019) FY 2019
Y / Y Total Assets Change	-35.46 %	-25.89 %	12.09 %	-22.38 %	-23.36 %
Total Assets in million	118	183	248	221	285
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-48	-148	-148	-99	-122
Annual Return On Assets	-40.5 %	-80.42 %	-59.92 %	-44.94 %	-43.03 %

GTHX's 5 Years Annual ROA >> Back to GTHX Management Effectiveness >> Compare GTHX ROA to its Competitors

More Return On Assets Ratios
GTHX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
GTHX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for GTHX's Competitors
Subscribers only: Roa for G1 Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for GTHX's Customers

You may also want to know
GTHX's Roi	GTHX's Inventory Turnover Ratio	GTHX's Growth Rates	GTHX's Dividend Comparisons
	GTHX's Profitability Ratios	GTHX's Asset Turnover Ratio	GTHX's Dividend Growth
GTHX's Roe	GTHX's Valuation Ratios	GTHX's Financial Strength Ratios	GTHX's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2024, within Healthcare Sector

ROA

Date modified: 2026-09-18T13:11:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.